Literature DB >> 2458846

Preferential expression of neo-CRP epitopes on the surface of human peripheral blood lymphocytes.

N L Samberg1, R A Bray, H Gewurz, A L Landay, L A Potempa.   

Abstract

Antibodies specific for C-reactive protein (CRP) have been reported to react with certain human peripheral blood lymphocytes (PBL); however, the nature of the antigen has not been clearly defined. In the present study we identified the CRP antigenicity on PBL as a CRP neoepitope not seen on the native-CRP molecule. Neo-CRP epitopes are expressed when the native pentameric form of CRP is dissociated into free subunits. Commercial anti-CRP antisera were found to possess a significant proportion of specificities (up to 16% of the total reactivity) directed against neo-CRP antigenicity. Since similar reagents had been used in previous studies on the reactivity of anti-CRP antisera with PBL, we set out to determine if either native- or neo-CRP epitopes were preferentially expressed on PBL. We prepared antisera monospecific for native-CRP and neo-CRP, respectively, and characterized these reactivities in both direct and indirect enzyme immunoassays. When analyzed by flow cytometry, anti-neo-CRP but not anti-native-CRP antiserum was found to react with normal PBL. F(ab')2 fragments of affinity-purified anti-neo-CRP had identical activity, and the reactivity against CRP was absorbed by reagents expressing neo-CRP but not native-CRP epitopes. Flow cytometric analyses of monocyte-depleted PBL from 25 normal donors detected a mean of 23.8 +/- 5.8% anti-neo-CRP-positive cells, a higher proportion of PBL expressing the CRP antigen than previously reported. Our findings indicate that a molecule identical to, or cross-reactive with, a neo-antigenic form of CRP is present on the surface of a significant proportion of normal human PBL.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2458846     DOI: 10.1016/0008-8749(88)90212-2

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  9 in total

1.  Binding of the monomeric form of C-reactive protein to enzymatically-modified low-density lipoprotein: effects of phosphoethanolamine.

Authors:  Sanjay K Singh; Madathilparambil V Suresh; David J Hammond; Antonio E Rusiñol; Lawrence A Potempa; Alok Agrawal
Journal:  Clin Chim Acta       Date:  2009-06-21       Impact factor: 3.786

2.  Antibodies against C-reactive protein cross-react with 60-kilodalton heat shock proteins.

Authors:  Katalin Udvarnoki; László Cervenak; Katalin Uray; Ferenc Hudecz; Imre Kacskovics; Ralf Spallek; Mahavir Singh; George Füst; Zoltán Prohászka
Journal:  Clin Vaccine Immunol       Date:  2007-02-14

Review 3.  A hypothesis resolving the apparently disparate activities of native and altered forms of human C-reactive protein.

Authors:  M J Shields
Journal:  Immunol Res       Date:  1993       Impact factor: 2.829

Review 4.  Targeting C-Reactive Protein in Inflammatory Disease by Preventing Conformational Changes.

Authors:  J R Thiele; J Zeller; H Bannasch; G B Stark; K Peter; S U Eisenhardt
Journal:  Mediators Inflamm       Date:  2015-05-18       Impact factor: 4.711

Review 5.  On the irrationality of rational design of an HIV vaccine in light of protein intrinsic disorder.

Authors:  Vladimir N Uversky
Journal:  Arch Virol       Date:  2021-02-19       Impact factor: 2.574

6.  Extrahepatic transcription of human C-reactive protein.

Authors:  T M Murphy; L L Baum; K D Beaman
Journal:  J Exp Med       Date:  1991-02-01       Impact factor: 14.307

7.  Serum levels of autoantibodies against monomeric C-reactive protein are correlated with disease activity in systemic lupus erythematosus.

Authors:  Christopher Sjöwall; Anders A Bengtsson; Gunnar Sturfelt; Thomas Skogh
Journal:  Arthritis Res Ther       Date:  2003-12-05       Impact factor: 5.156

8.  Solubilization and purification of recombinant modified C-reactive protein from inclusion bodies using reversible anhydride modification.

Authors:  Lawrence A Potempa; Zhen-Yu Yao; Shang-Rong Ji; János G Filep; Yi Wu
Journal:  Biophys Rep       Date:  2015-07-18

Review 9.  Biology of natural killer cells.

Authors:  G Trinchieri
Journal:  Adv Immunol       Date:  1989       Impact factor: 3.543

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.